Mycobacterium tuberculosis virulence: insights and impact on vaccine development

Giovanni Delogu, Michela Sali, Roberta Provvedi, Riccardo Manganelli

Research output: Contribution to journalArticle

12 Citations (Scopus)


The existing TB vaccine, the attenuated Mycobacterium bovis strain BCG, is effective in protecting infants from severe forms of the disease, while its efficacy in protecting adults from pulmonary TB is poor. In the last two decades, a renewed interest in TB resulted in the development of several candidate vaccines that are now entering clinical trials. However, most of these vaccines are based on a common rationale and aim to induce a strong T-cell response against Mycobacterium tuberculosis. Recent advancements in the understanding of M. tuberculosis virulence determinants and associated pathogenic strategies are opening a new and broader view of the complex interaction between this remarkable pathogen and the human host, providing insights at molecular level that could lead to a new rationale for the design of novel antitubercular vaccines. A vaccination strategy that simultaneously targets different steps in TB pathogenesis may result in improved protection and reduced TB transmission.
Original languageEnglish
Pages (from-to)1177-1194
Number of pages18
JournalFuture Microbiology
Publication statusPublished - 2015


  • BCG
  • immunity
  • infectious diseases
  • pathogenicity
  • tuberculosis
  • vaccine
  • virulence


Dive into the research topics of 'Mycobacterium tuberculosis virulence: insights and impact on vaccine development'. Together they form a unique fingerprint.

Cite this